 Matthew Sikora
Concepts (254)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Lobular | 10 | 2022 | 49 | 2.800 |
Why?
| | Breast Neoplasms | 24 | 2025 | 2253 | 2.420 |
Why?
| | Receptors, Estrogen | 10 | 2025 | 436 | 2.400 |
Why?
| | Wnt4 Protein | 4 | 2024 | 18 | 2.090 |
Why?
| | Antineoplastic Agents, Hormonal | 6 | 2025 | 161 | 1.550 |
Why?
| | Estrogens | 7 | 2025 | 367 | 1.430 |
Why?
| | Estrogen Receptor alpha | 9 | 2023 | 145 | 1.320 |
Why?
| | Drug Resistance, Neoplasm | 9 | 2025 | 801 | 1.060 |
Why?
| | Tamoxifen | 7 | 2021 | 202 | 0.810 |
Why?
| | Genital Neoplasms, Female | 1 | 2024 | 90 | 0.780 |
Why?
| | Genital Diseases, Female | 1 | 2021 | 28 | 0.720 |
Why?
| | Genitalia, Female | 1 | 2021 | 38 | 0.710 |
Why?
| | MCF-7 Cells | 10 | 2021 | 124 | 0.700 |
Why?
| | Gene Expression Regulation, Neoplastic | 12 | 2025 | 1396 | 0.700 |
Why?
| | Cell Proliferation | 12 | 2021 | 2475 | 0.670 |
Why?
| | Estradiol | 7 | 2023 | 521 | 0.670 |
Why?
| | Spinal Curvatures | 1 | 2020 | 4 | 0.660 |
Why?
| | Cell Line, Tumor | 17 | 2025 | 3412 | 0.660 |
Why?
| | Cell Cycle Proteins | 2 | 2021 | 617 | 0.650 |
Why?
| | Wnt3A Protein | 1 | 2019 | 10 | 0.650 |
Why?
| | Acyltransferases | 1 | 2019 | 57 | 0.630 |
Why?
| | Ovarian Neoplasms | 6 | 2024 | 565 | 0.620 |
Why?
| | Psychological Tests | 1 | 2020 | 140 | 0.610 |
Why?
| | Wnt Signaling Pathway | 2 | 2019 | 192 | 0.590 |
Why?
| | Women's Health | 1 | 2021 | 372 | 0.580 |
Why?
| | Spine | 1 | 2020 | 173 | 0.580 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2021 | 430 | 0.570 |
Why?
| | Orthopedic Procedures | 1 | 2020 | 216 | 0.540 |
Why?
| | Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2017 | 31 | 0.540 |
Why?
| | Receptors, Mineralocorticoid | 1 | 2016 | 10 | 0.530 |
Why?
| | Anxiety Disorders | 1 | 2020 | 377 | 0.510 |
Why?
| | Serum | 1 | 2016 | 59 | 0.500 |
Why?
| | Depressive Disorder, Major | 1 | 2020 | 364 | 0.490 |
Why?
| | Receptors, Androgen | 1 | 2016 | 150 | 0.480 |
Why?
| | Signal Transduction | 8 | 2024 | 5079 | 0.470 |
Why?
| | Receptors, Glucocorticoid | 1 | 2016 | 155 | 0.470 |
Why?
| | Receptors, Progesterone | 1 | 2016 | 350 | 0.450 |
Why?
| | Neoplasm Invasiveness | 6 | 2020 | 510 | 0.440 |
Why?
| | Aromatase Inhibitors | 2 | 2018 | 54 | 0.430 |
Why?
| | Deep Brain Stimulation | 3 | 2020 | 153 | 0.410 |
Why?
| | Membrane Proteins | 1 | 2019 | 1164 | 0.400 |
Why?
| | Tumor Microenvironment | 3 | 2024 | 674 | 0.390 |
Why?
| | Cytochrome P-450 CYP2D6 | 4 | 2017 | 30 | 0.360 |
Why?
| | Gene Expression | 2 | 2014 | 1502 | 0.360 |
Why?
| | Benzoxazines | 1 | 2010 | 31 | 0.340 |
Why?
| | Estrogen Antagonists | 1 | 2010 | 45 | 0.330 |
Why?
| | Risk Assessment | 1 | 2020 | 3457 | 0.330 |
Why?
| | Paraffin Embedding | 1 | 2010 | 32 | 0.330 |
Why?
| | Genotyping Techniques | 1 | 2010 | 75 | 0.330 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2010 | 84 | 0.330 |
Why?
| | Female | 34 | 2025 | 73304 | 0.320 |
Why?
| | Psoriasis | 2 | 2021 | 102 | 0.320 |
Why?
| | Humans | 45 | 2025 | 137585 | 0.320 |
Why?
| | Androstane-3,17-diol | 1 | 2008 | 2 | 0.300 |
Why?
| | Gossypol | 1 | 2008 | 1 | 0.300 |
Why?
| | Models, Biological | 2 | 2012 | 1783 | 0.280 |
Why?
| | Carcinoma, Ductal, Breast | 3 | 2022 | 83 | 0.260 |
Why?
| | Breast | 3 | 2022 | 151 | 0.250 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2025 | 2 | 0.240 |
Why?
| | Receptor, ErbB-2 | 2 | 2019 | 341 | 0.240 |
Why?
| | Antioxidants | 1 | 2008 | 584 | 0.220 |
Why?
| | Carbonyl Reductase (NADPH) | 1 | 2024 | 5 | 0.220 |
Why?
| | Neoplasms | 2 | 2010 | 2671 | 0.220 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2024 | 77 | 0.210 |
Why?
| | DNA | 1 | 2010 | 1459 | 0.200 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2024 | 197 | 0.190 |
Why?
| | Selective Estrogen Receptor Modulators | 3 | 2017 | 29 | 0.190 |
Why?
| | Ligands | 1 | 2024 | 664 | 0.180 |
Why?
| | Analgesics, Opioid | 2 | 2020 | 1000 | 0.180 |
Why?
| | Sex Differentiation | 1 | 2021 | 10 | 0.180 |
Why?
| | Sexual Development | 1 | 2021 | 18 | 0.180 |
Why?
| | Mammary Glands, Human | 1 | 2021 | 64 | 0.170 |
Why?
| | RNA Interference | 2 | 2019 | 469 | 0.170 |
Why?
| | Pain, Postoperative | 2 | 2020 | 265 | 0.170 |
Why?
| | Neuroma, Acoustic | 1 | 2021 | 51 | 0.170 |
Why?
| | Protein Binding | 2 | 2016 | 2224 | 0.170 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 63 | 0.170 |
Why?
| | Genotype | 3 | 2017 | 1916 | 0.160 |
Why?
| | Uterus | 1 | 2021 | 215 | 0.160 |
Why?
| | Laminectomy | 1 | 2020 | 31 | 0.160 |
Why?
| | Diskectomy | 1 | 2020 | 23 | 0.160 |
Why?
| | Preoperative Period | 1 | 2020 | 129 | 0.160 |
Why?
| | Culture Media, Conditioned | 1 | 2019 | 110 | 0.160 |
Why?
| | Cell Survival | 2 | 2016 | 1120 | 0.160 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2020 | 66 | 0.160 |
Why?
| | Paracrine Communication | 1 | 2019 | 65 | 0.160 |
Why?
| | Snail Family Transcription Factors | 1 | 2019 | 17 | 0.150 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 389 | 0.150 |
Why?
| | Coculture Techniques | 1 | 2019 | 239 | 0.150 |
Why?
| | Phthalazines | 1 | 2019 | 45 | 0.150 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2021 | 2189 | 0.150 |
Why?
| | Gene Amplification | 1 | 2019 | 104 | 0.150 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2019 | 98 | 0.150 |
Why?
| | Clinical Protocols | 1 | 2020 | 271 | 0.150 |
Why?
| | Gene Expression Profiling | 2 | 2018 | 1774 | 0.150 |
Why?
| | Estrogen Receptor Antagonists | 1 | 2017 | 3 | 0.140 |
Why?
| | Neurosurgical Procedures | 1 | 2020 | 197 | 0.140 |
Why?
| | Endometriosis | 1 | 2018 | 51 | 0.140 |
Why?
| | Protein Transport | 1 | 2019 | 445 | 0.140 |
Why?
| | Neoadjuvant Therapy | 1 | 2020 | 404 | 0.140 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2019 | 115 | 0.140 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2019 | 220 | 0.140 |
Why?
| | Machine Learning | 2 | 2020 | 493 | 0.140 |
Why?
| | Middle Aged | 11 | 2024 | 33479 | 0.140 |
Why?
| | Transcriptome | 2 | 2021 | 971 | 0.140 |
Why?
| | RNA, Small Interfering | 1 | 2019 | 622 | 0.130 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2017 | 39 | 0.130 |
Why?
| | Fishes | 1 | 2017 | 105 | 0.130 |
Why?
| | Piperazines | 1 | 2019 | 350 | 0.130 |
Why?
| | Antineoplastic Agents | 1 | 2008 | 2129 | 0.130 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2012 | 2057 | 0.130 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 455 | 0.130 |
Why?
| | Promoter Regions, Genetic | 1 | 2021 | 1250 | 0.130 |
Why?
| | Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2016 | 12 | 0.130 |
Why?
| | Androstenes | 1 | 2016 | 18 | 0.130 |
Why?
| | Polymorphism, Genetic | 2 | 2017 | 660 | 0.120 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 307 | 0.120 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 121 | 0.120 |
Why?
| | Cell Culture Techniques | 1 | 2018 | 363 | 0.120 |
Why?
| | Neoplasm Staging | 2 | 2017 | 1389 | 0.120 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2016 | 49 | 0.120 |
Why?
| | Proto-Oncogene Proteins | 1 | 2019 | 648 | 0.120 |
Why?
| | Reproduction | 1 | 2017 | 204 | 0.120 |
Why?
| | Animals | 7 | 2021 | 36940 | 0.120 |
Why?
| | Algorithms | 2 | 2020 | 1704 | 0.120 |
Why?
| | Lipid Metabolism | 1 | 2018 | 518 | 0.110 |
Why?
| | Comorbidity | 1 | 2020 | 1622 | 0.110 |
Why?
| | Pilot Projects | 1 | 2020 | 1710 | 0.110 |
Why?
| | Prognosis | 5 | 2024 | 4030 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1692 | 0.110 |
Why?
| | Retrospective Studies | 6 | 2021 | 15657 | 0.110 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2014 | 53 | 0.100 |
Why?
| | Aged | 7 | 2024 | 23961 | 0.100 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 1040 | 0.100 |
Why?
| | Biomarkers, Tumor | 2 | 2019 | 1276 | 0.100 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 1079 | 0.100 |
Why?
| | Mutation | 2 | 2021 | 3958 | 0.100 |
Why?
| | NF-kappa B | 1 | 2016 | 691 | 0.100 |
Why?
| | Opioid-Related Disorders | 1 | 2020 | 515 | 0.090 |
Why?
| | Smoking | 1 | 2019 | 1627 | 0.090 |
Why?
| | Mice | 5 | 2021 | 17787 | 0.090 |
Why?
| | Phenotype | 2 | 2018 | 3196 | 0.090 |
Why?
| | Quality Improvement | 1 | 2020 | 1178 | 0.090 |
Why?
| | Postoperative Complications | 2 | 2021 | 2654 | 0.090 |
Why?
| | Gynecomastia | 1 | 2010 | 6 | 0.090 |
Why?
| | Inhibitory Concentration 50 | 1 | 2010 | 90 | 0.080 |
Why?
| | Cyclopropanes | 1 | 2010 | 90 | 0.080 |
Why?
| | Alkynes | 1 | 2010 | 56 | 0.080 |
Why?
| | Microarray Analysis | 1 | 2010 | 117 | 0.080 |
Why?
| | Formaldehyde | 1 | 2010 | 63 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 976 | 0.080 |
Why?
| | Inflammation | 1 | 2020 | 2837 | 0.080 |
Why?
| | Polyunsaturated Alkamides | 1 | 2008 | 8 | 0.070 |
Why?
| | Cell Cycle Checkpoints | 2 | 2019 | 98 | 0.070 |
Why?
| | Estrogen Receptor Modulators | 1 | 2008 | 17 | 0.070 |
Why?
| | In Vitro Techniques | 1 | 2010 | 1092 | 0.070 |
Why?
| | Pregnancy | 1 | 2021 | 6763 | 0.070 |
Why?
| | Genetic Association Studies | 1 | 2010 | 377 | 0.070 |
Why?
| | Arachidonic Acids | 1 | 2008 | 62 | 0.070 |
Why?
| | Hot Flashes | 1 | 2009 | 87 | 0.070 |
Why?
| | Treatment Outcome | 2 | 2020 | 10811 | 0.070 |
Why?
| | Oxidants | 1 | 2008 | 111 | 0.070 |
Why?
| | Phosphorylation | 1 | 2012 | 1759 | 0.070 |
Why?
| | Acetylcysteine | 1 | 2008 | 145 | 0.070 |
Why?
| | Drug Synergism | 1 | 2008 | 382 | 0.070 |
Why?
| | Heterografts | 2 | 2019 | 138 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 1062 | 0.070 |
Why?
| | Androgens | 1 | 2008 | 187 | 0.060 |
Why?
| | Male | 6 | 2020 | 67762 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 767 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 1 | 2012 | 916 | 0.060 |
Why?
| | Cadherins | 2 | 2018 | 206 | 0.060 |
Why?
| | Blotting, Western | 1 | 2008 | 1226 | 0.060 |
Why?
| | Reactive Oxygen Species | 1 | 2008 | 622 | 0.060 |
Why?
| | Survival Rate | 2 | 2020 | 1972 | 0.060 |
Why?
| | Patient Compliance | 1 | 2009 | 581 | 0.060 |
Why?
| | Neoplasm Grading | 1 | 2024 | 307 | 0.050 |
Why?
| | Patient Discharge | 2 | 2020 | 897 | 0.050 |
Why?
| | Cells, Cultured | 1 | 2010 | 4193 | 0.050 |
Why?
| | Cell Line | 1 | 2008 | 2847 | 0.050 |
Why?
| | Pancreatic Neoplasms | 1 | 2010 | 938 | 0.050 |
Why?
| | Databases, Genetic | 1 | 2023 | 237 | 0.050 |
Why?
| | Biology | 1 | 2022 | 88 | 0.040 |
Why?
| | Etanercept | 1 | 2020 | 57 | 0.040 |
Why?
| | Ustekinumab | 1 | 2020 | 15 | 0.040 |
Why?
| | Microsurgery | 1 | 2021 | 75 | 0.040 |
Why?
| | Adalimumab | 1 | 2020 | 48 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2020 | 5131 | 0.040 |
Why?
| | Ubiquitination | 1 | 2020 | 102 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 1 | 2009 | 2426 | 0.040 |
Why?
| | Apoptosis | 2 | 2019 | 2553 | 0.040 |
Why?
| | Proteolysis | 1 | 2020 | 177 | 0.040 |
Why?
| | Narcotics | 1 | 2020 | 52 | 0.040 |
Why?
| | Adult | 5 | 2021 | 37929 | 0.040 |
Why?
| | Movement Disorders | 1 | 2019 | 58 | 0.040 |
Why?
| | Indazoles | 1 | 2019 | 69 | 0.040 |
Why?
| | Oxysterols | 1 | 2018 | 2 | 0.040 |
Why?
| | Postoperative Period | 1 | 2020 | 342 | 0.040 |
Why?
| | Fatty Acid Synthase, Type I | 1 | 2018 | 11 | 0.040 |
Why?
| | Adherens Junctions | 1 | 2018 | 25 | 0.040 |
Why?
| | Morphine | 1 | 2020 | 158 | 0.040 |
Why?
| | Sterol Regulatory Element Binding Protein 1 | 1 | 2018 | 57 | 0.040 |
Why?
| | DNA Copy Number Variations | 1 | 2019 | 182 | 0.040 |
Why?
| | Drug Prescriptions | 1 | 2020 | 245 | 0.040 |
Why?
| | Collagen Type I | 1 | 2018 | 136 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2020 | 465 | 0.030 |
Why?
| | Piperidines | 1 | 2019 | 206 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1236 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2019 | 955 | 0.030 |
Why?
| | Pharmacogenomic Variants | 1 | 2017 | 35 | 0.030 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2019 | 209 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2018 | 466 | 0.030 |
Why?
| | Patient Safety | 1 | 2020 | 314 | 0.030 |
Why?
| | RNA, Neoplasm | 1 | 2016 | 82 | 0.030 |
Why?
| | Indoles | 1 | 2019 | 412 | 0.030 |
Why?
| | DNA, Neoplasm | 1 | 2016 | 164 | 0.030 |
Why?
| | Length of Stay | 1 | 2021 | 1215 | 0.030 |
Why?
| | Risk Factors | 2 | 2020 | 10388 | 0.030 |
Why?
| | Mice, SCID | 1 | 2016 | 367 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 528 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2017 | 889 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 658 | 0.030 |
Why?
| | Extracellular Matrix | 1 | 2018 | 528 | 0.030 |
Why?
| | Alleles | 1 | 2017 | 891 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2031 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1325 | 0.030 |
Why?
| | Cell Movement | 1 | 2018 | 967 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2017 | 872 | 0.030 |
Why?
| | Genome | 1 | 2016 | 300 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2016 | 434 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2020 | 2828 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2016 | 1738 | 0.020 |
Why?
| | Registries | 1 | 2019 | 2035 | 0.020 |
Why?
| | Disease Progression | 1 | 2018 | 2757 | 0.020 |
Why?
| | Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2010 | 13 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2010 | 189 | 0.020 |
Why?
| | DNA Primers | 1 | 2010 | 515 | 0.020 |
Why?
| | 8,11,14-Eicosatrienoic Acid | 1 | 2008 | 6 | 0.020 |
Why?
| | Microsomes | 1 | 2008 | 33 | 0.020 |
Why?
| | Hydroxylation | 1 | 2008 | 39 | 0.020 |
Why?
| | Mice, Nude | 1 | 2010 | 698 | 0.020 |
Why?
| | Epoxy Compounds | 1 | 2008 | 33 | 0.020 |
Why?
| | Arachidonic Acid | 1 | 2008 | 120 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2016 | 2833 | 0.020 |
Why?
| | Endocannabinoids | 1 | 2008 | 63 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2010 | 1272 | 0.020 |
Why?
| | Base Sequence | 1 | 2010 | 2181 | 0.020 |
Why?
| | Young Adult | 1 | 2019 | 13209 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2010 | 3284 | 0.010 |
Why?
| | Mitochondria | 1 | 2008 | 948 | 0.010 |
Why?
| | Cohort Studies | 1 | 2009 | 5742 | 0.010 |
Why?
| | Time Factors | 1 | 2008 | 6828 | 0.010 |
Why?
| | Prospective Studies | 1 | 2009 | 7604 | 0.010 |
Why?
| | Brain | 1 | 2008 | 2668 | 0.010 |
Why?
|
|
Sikora's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|